comparemela.com

Latest Breaking News On - Pharmather holdings - Page 3 : comparemela.com

PharmaTher Provides Update for Expected FDA Approval of Ketamine

Assigned FDA approval goal date of April 29, 2024, is still on trackTORONTO, Jan. 10, 2024 PharmaTher Holdings Ltd. , a specialty pharmaceutical company, is pleased to provide an update for.

Fabio chianelliHealth canadaNeither the canadian securities exchangeRisk factors in companyDrug administrationCompany or pharmatherRegulation services providerPharmather holdings ltdMother holdingsAbbreviated new drug applicationAmyotrophic lateral sclerosisRett syndromeComplex regional pain syndromeCanadian securities exchangePharmather holdings

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)

FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 .

Fabio chianelliRegulation services providerVitruvias therapeutics incDrug administrationCompany or pharmatherNeither the canadian securities exchangeRisk factors in companyHealth canadaPharmather holdings ltdMother holdingsAbbreviated new drug applicationGeneric drug user fee amendmentsVitruvias therapeuticsCanadian securities exchangePharmather holdings

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years - Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI)

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

United statesPharmather holdingsNuminus wellnessJanssen pharmaceuticalsAsia pacificGen psychiatry solutionsResearch nesterMind medicineMindset pharmaLeap into next gen psychiatryNorth american

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

TORONTO, Sept. 06, 2023 PharmaTher Holdings Ltd. , a commercial-focused specialty pharmaceutical company, is pleased to announce it has submitted a priority original Abbreviated New Drug.

Fabio chianelliPharmather holdings ltdHealth canadaDrug administrationNeither the canadian securities exchangeCompany or pharmatherRegulation services providerRisk factors in companyVitruvias therapeutics incMother holdingsAbbreviated new drug applicationVitruvias therapeuticsCanadian securities exchangePharmather holdings

PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application - PharmaTher Holdings (OTC:PHRRF)

Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t

Pharmather holdingsFabio chianelliAbbreviated new drug application

vimarsana © 2020. All Rights Reserved.